# Referral patterns in the CKD.QLD Registry: a call for revisiting the definition of late referral

**Clyson Mutatiri[1,2]*, Angela Ratsch [3,4], Matthew McGrail[5], Sree Krishna Venuthurupalli [6,7] and Srinivas Kondalsamy- Chennakesavan[8,9]**

[1]Renal Medicine, Bundaberg Base Hospital, Wide Bay Hospital and Health Service, 271 Bourbong St, Bundaberg Central QLD 4670, Australia; Email: clyson.mutatiri@health.qld.gov.au, Ph: +61 7 41502222, Fax: +61 41502449

[2]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Bundaberg, Queensland, Australia.

[3]Research Services, Wide Bay Hospital and Health Service, Hervey Bay, Queensland, Australia

[4]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Hervey Bay, Queensland, Australia

[5] Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Rockhampton, Queensland, Australia

[6] Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, Ipswich, Queensland, Australia

[7]Kidney Service, Department of Medicine, West Moreton Hospital and Health Service, Ipswich, Queensland, Australia

[8]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Toowoomba, Queensland, Australia

[9] School of Health and Medical Sciences, University of Southern Queensland, Toowoomba, Queensland, Australia

***Corresponding author**

**Key words:** Chronic kidney disease, late referral, estimated glomerular filtration rate, urine albumin-to-creatinine ratio, Kidney Health Australia, kidney failure risk equation

# Abstract

## Background

The rising burden of chronic kidney disease (CKD) requires reinforcing of the current mechanisms for early detection and intervention. Although 'timely' referral to a specialist nephrology service plays a crucial role for many patients in ensuring improved outcomes, the lack of widely accepted definitions of timely (and by implication, early and late) referral may limit such outcomes.

## Study aim

To evaluate referral patterns among CKD.QLD Registry participants, focusing on the timing and appropriateness of referrals and their association with clinical outcomes.

## Methods

We conducted a retrospective cohort study of adults (≥18 years) enrolled in the CKD.QLD Registry from seven public nephrology clinics between May 2011 and June 2018. Participants were followed until kidney replacement therapy (KRT), death, or study closure. All CKD stages were included to assess demographic and clinical characteristics at referral and associated outcomes. Late referral was defined as initiation of KRT within 12 months of the first nephrology visit among those who progressed to KRT.

## Results

Among 3,775 participants (median age 65 years; 54.8% male; 8.7% Indigenous), hypertension (77.5%) and type 2 diabetes (44.9%) were the most common comorbidities. ESKD developed in 775 (20.5%) participants; 513 (66.2%) received KRT. Overall, 722 (19.1%) died, including 124 (17.2%) after starting KRT. Late referral occurred in 60 (11.7%) KRT participants, with

15 (25%) deaths, 3 within 12 months of KRT initiation. Most KRT patients (77.4%) and deaths (65.5%) were in the high-comorbidity group; among KRT-related deaths, 101 (81.5%) were high-comorbidity, and 351 (88.4%) were referred early.

## Conclusion

Late referral rates were lower than previously reported. Comorbidity burden, rather than referral timing, was the stronger predictor of mortality. These findings highlight the need for a standardized definition of late referral that incorporates risk stratification.

# Introduction

Chronic kidney disease (CKD) is a globally recognised contributor to increasing mortality and morbidity, with an estimated worldwide prevalence of 13.4% [1]. The burden of CKD is disproportionately borne by low-income countries and socio-economically disadvantaged populations [2]. With increasing life expectancy, coupled with increasing prevalence of key risk factors such as diabetes mellitus (DM) and hypertension, CKD has emerged as a critical public health concern and drain on resources for health systems globally [3]. Early identification and intervention are crucial for slowing the progression of CKD and improving patient outcomes[4].

Early-stage CKD is predominately managed within primary care settings [5]. However, a subset of these patients will ultimately require referral to nephrology clinics for specialist input, particularly as their disease advances or if they develop complications [6]. Traditionally, the referral of individuals with CKD from primary care to specialist nephrology services has been guided by established protocols, such as those outlined by international bodies including Kidney Disease: Improving Global Outcomes (KDIGO) [7], Kidney Health Australia (KHA) [8], and other globally recognised guidelines. The timing of referral has historically been

70 considered a critical factor influencing outcomes, with the evidence demonstrating that earlier
71 referral allows for better preparation for kidney replacement therapy (KRT), optimised
72 management of comorbidities, and improved survival [9]. Late referral generally refers to
73 patients who had commenced KRT such as dialysis or kidney transplantation within a short
74 period (ranging from 1 to 12 months) following their initial nephrology clinic visit [10]. While
75 there is no universally agreed-upon timeframe, this operational time-based definition is widely
76 utilised in clinical studies [11].

77 Multiple studies have reported that late referral is associated with worse clinical outcomes,
78 including higher mortality rates, increased rates of hospitalisation, and poorer quality of life
79 [12, 13]. These adverse outcomes have been attributed to insufficient pre-dialysis education,
80 suboptimal management of anaemia, mineral bone disorder, and delayed preparation for
81 vascular access or transplantation [9]. However, the landscape of CKD management has
82 evolved considerably in recent years. Advances in the understanding of CKD pathophysiology,
83 the introduction of a working system based on estimated glomerular filtration rate (eGFR) and
84 albuminuria, and the recognition of albuminuria as an important marker for early detection and
85 risk stratification have all contributed to improved care [14, 15]. The emergence of
86 renoprotective pharmacological therapies, such as renin-angiotensin-aldosterone system
87 (RAAS) inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and statins, has
88 enabled primary care clinicians to modify the risk of CKD progression, cardiovascular disease
89 (CVD), and mortality at an earlier stage [16]. As a result, risk factor modification and the
90 application of guideline-based therapy are increasingly being implemented in primary care
91 settings before referral to nephrology [4]. The focus has shifted from simply managing eGFR
92 thresholds to a more holistic approach that includes blood pressure control, optimising
93 glycaemic management in diabetes, and the use of agents that offer renoprotection [17, 18].

Given this evolution in CKD care, the question arises: does the timing of referral to nephrology clinics still matter as a determinant of outcomes, particularly death following the initiation of KRT? To address this, we conducted a retrospective analysis of participants enrolled in the Chronic Kidney Disease Queensland Registry (CKD.QLD) to evaluate whether late referral continues to impact outcomes in patients who progressed to KRT. Additionally, the study seeks to critically evaluate and potentially refine the current operational definition of late referral from primary care to nephrology services.

# Methods

## Data source and methods of data collection

The Chronic Kidney Disease in Queensland (CKD.QLD) was established as a collaborative of most public sector kidney care practices in Queensland in May 2011. The CKD.QLD data collection methods have been described by Venuthurapalli *et al*, briefly however, the main objective of the registry was to profile participants with CKD, promoting CKD surveillance, practice improvement and research within the kidney care practice network in the public health system in QLD [19]. Data linkage framework was used to centralise data captured by multiple mechanisms to an individual participant via a unique identifier. This enabled further characterisation of participants with CKD, providing a comprehensive view of the health services utilisation and costs and outcomes of people with CKD.

Adult participants aged 18 years and above with the diagnosis of CKD presenting to public ambulatory nephrology clinics in the QLD health (QH) system were consented to have their demographic and clinical data collected. More than 7,600 participants consented to be part of the Registry between June 2011 and June 2018. Excluded were patients on kidney replacement therapy (KRT) and those with acute kidney injury (AKI) unless they subsequently developed and met the diagnostic criteria for CKD. Participants were followed until the start of KRT,

death or 30 June 2018. For the current study, we excluded participants whose date of referral to the nephrology clinic couldn't be established.

The demographic variables recorded included age, gender, ethnicity and geographical location, identified by postcode, as well as laboratory and clinical variables and outcome measures. Variables of interest which were not already in the database were manually collected from integrated electronic Medical Record (ieMR), the Hospital Based Corporate Information System (HBCIS), other QLD health platforms, and from private pathology laboratories as appropriate, following granting of a Public Health Act (PHA) approval. Where only urine protein-to-creatinine ratio (PCR) and dipstick protein were available, the equations developed by Sumida et al were employed to calculate the predicted urine albumin-to-creatinine ratio (UACR)[20]. The eGFR was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation). Data extraction was undertaken between 18 January 2021 and 15 June 2025 in compliance with ethics and PHA approvals.

## Study design and population

This retrospective cohort study utilised data from participants aged ≥18 years enrolled in the CKD.QLD Registry between 1 May 2011 and 30 June 2018 from seven public healthcare nephrology clinics. A description of participants and basic study outcomes were previously detailed in a published protocol [21].

## Outcomes and variables

Primary outcomes included progression to end-stage kidney disease (ESKD), commencement of KRT, and mortality before and after commencement of KRT. Demographic and clinical variables were investigated for their potential role as predictors or covariates of these outcomes. Referral timing to nephrology services was assessed and defined by the conventional method as the interval between the first encounter with the nephrology service and commencement of

KRT. Late referral was defined as commencing KRT within 12 months of the first visit to the nephrology clinic, amongst those who progressed to KRT.

The kidney failure risk equation (KFRE) was applied to participants with CKD stages G3 to G5 at the time of referral and available urine albumin-to-creatinine ratio (UACR) data to calculate the risk of progression to KRT. Socio-Economic Indexes for Areas (SEIFA) Relative Socio-economic Disadvantage (IRSD) scores as produced by the Australian Bureau of Statistics were used to measure socioeconomic status of the enrolled participants by their residential postcode [22]. The IRSD deciles were regrouped into quintiles (lowest, low, middle, high, and highest) with the highest quintile representing the least disadvantaged postal areas and the lowest quintile representing the most disadvantaged postal areas [23]. Participants were further categorised into 3 levels of socio-economic status by combining the two lowest quintiles into the low socio-economic status group, the two highest quintiles into the high socio-economic status group, and the middle quintile into the middle socio-economic status group. Participants with a recorded BMI were divided into obese (BMI ≥30) and non-obese (BMI <30). Comorbidity burden was dichotomised into low (0 to 2 comorbidities) and high (3 or more comorbidities).

## Data Analysis

Descriptive statistics and basic inferential statistics were employed to summarise demographic and clinical characteristics, exploring basic data patterns and describing referral patterns. Categorical variables were presented as proportions (numbers and percentages) and continuous variables as means with standard deviations. Associations between time of referral and the outcomes of death and KRT initiation were explored using a Cox proportional hazards regression model. The initial multivariable model assessed the rate of mortality against the following predictors: age at referral, eGFR at referral, gender, indigenous status,

166 socioeconomic status, primary renal disease (PRD), comorbidity score, and the comorbidities
167 of DM, CVD, hypertension, coronary artery disease (CAD), and the timing of referral presented
168 as late referral. The final model excluded variables with little univariate significance, (p-value
169 of >0.2) and summarized hazard ratios (HR) and 95% confidence intervals (95% CIs). The
170 Log-rank test was used to compare the difference of survival by referral groups, and the
171 Kaplan-Meier survival curve was used to depict the survival differences between the late and
172 early referred groups after KRT initiation. All analyses used STATA version 18 and $p < 0.05$
173 as the threshold for statistical significance.

# 174 Ethical considerations

175 Approval for the study was granted by the Ethics Committee of the Royal Brisbane and
176 Women's Hospital in January 2021 (LNR/2020/QRBW/69707 14/01/2021). The requirement
177 for individual consent was waived as all patients had consented for the use of their data for the
178 purpose of research on recruitment into CKD.QLD Registry. Additionally, a Public Health Act
179 approval (QCOS/029817/ RD006802) was granted in August 2023 for the release of missing
180 patient data held by the contributing Queensland Health Hospital and Health Services.

# 181 Results

## 182 Study sample characteristics

183 Figure 1 outlines the participant selection process. A total of 3,775 participants were included
184 in the final analysis with median age of 65 years (mean 62.5). Of these, 2,068 (54.8%) were
185 male and 327 (8.7%) identified as Indigenous Australians (Table 1).

186 Socioeconomic status, as measured by the IRSD, revealed that a significant portion of the
187 participants (1,806, 47.8%) lived in the most disadvantaged postal areas (low socioeconomic

188 status) (Table 1). This group represented the largest proportion of participants across all stages
189 of CKD (Table 1).

190 At the time of referral, nearly half of the participants, 1,872 (49.6%) were in stage G3 CKD
191 (G3A and G3B), whereas 713 (18.9%) were in stages 1 or 2 (eGFR of ≥60ml/min/1.73m$^2$).
192 CKD stages G4 and 5 accounted for 1,190 (31.5%) participants, predominately G4 (Table 1).
193 UACR data were available for 2,605 (69%) participants, with 920 (35.3%) exhibiting a UACR
194 of ≥ 30mg/mmol (Table S1).

195 There were 17 types of comorbidities recorded, with the number of comorbidities ranging from
196 0 to 15 per participant. A high proportion met the high comorbidity score criteria (range 63%-
197 70%) in all stages of CKD (Table 1). There were twice as many participants in the high
198 comorbidity group (67.6%) of whom 1,737 (68.1%) had an eGFR of ≥30 ml/min at the time of
199 referral (Table S2). Hypertension was the most common comorbidity, present in 77.5% of
200 participants, followed by DM and cardiovascular disease (CVD), 44.9% and 40.7%
201 respectively (Table 1).

## 202 Referral thresholds and outcomes

203 Around one third of participants (1,194, 31.6%) fulfilled the KHA eGFR threshold
204 (<30ml/min) for specialist referral (Table S2). Among the 2,581 (68.4%) who did not fulfill
205 the eGFR threshold, 216 (8.4%) progressed to KRT while 331 (12.8%) died without KRT
206 (Table S2). Similarly, though 1,685 (64.7%) participants did not fulfil the UACR threshold of
207 ≥30 mg/mmol for referral, of these 191 (11.3%) progressed to KRT while 221 (13.1%) died
208 without KRT (Table S1).

209 Of the 2,605 participants with both eGFR and UACR data, 371 (14.2%) met both referral
210 criteria, of which 150 (40.4%) subsequently requiring KRT (Table S3). Conversely, 1,203

211 (46.2%) did not meet either threshold for referral, yet 79 (6.6%) of these went on to require
212 KRT at some point during the period of follow up (Table S3).

## 213 Mortality and progression to ESKD

214 During the follow up period, 722 (19.1%) participants died, with the majority (598, 82.8%)
215 dying prior to commencing KRT, while 775 (21%) participants progressed to ESKD, of whom
216 513 (66.2%) received KRT (Table 1). Nearly half of all deaths (356, 49.3%) occurred among
217 participants from the low socioeconomic status group (Figure 2).

218 The Cox proportional hazards regression model indicated that participants who had been under
219 nephrology care for less than 12 months before starting KRT (late referral) had a 54% lower
220 hazard rate of mortality compared to those who had received care for more than 12 months
221 (HR <12 months, 0.46; 95% CI, 0.27 to 0.79; p = 0.01) (Table 2). The Log-rank test showed a
222 statistically significant difference in survival between the referral groups (p = 0.002) (Table
223 S4). The Kaplan-Meier survival curve shows longer survival after KRT initiation in the late
224 referred group (Figure 3). Advancing age was associated with increased mortality rate, with
225 each 5-year increment corresponding to a 15% increase in the hazard of death (HR = 1.15).
226 Additionally, the presence of cardiovascular disease was associated with a nearly twofold
227 increase in mortality rate (HR = 1.90) (Table 2).

## 228 Referral timing and comorbidity

229 Of the 513 participants who commenced KRT, 60 (11.7%) were classified as late referrals.
230 Among these, 32 (53.3%) were from low socioeconomic group, compared to 20 (33.3%) from
231 high socioeconomic group (Table 3).

232 Most participants who started KRT (397, 77.4%) and most who died (473, 65.5%) were in the
233 high comorbidity group (Table 2). Of those who died after starting KRT, (101, 81.5%) were

234 from the high comorbidity group, most of whom (351, 88.4%) had been referred early (Table
235 S5). Only 15 (12.1%) of those who died post-KRT were late referrals, with 3 (20%) of these
236 dying in the first 12 months of starting KRT (Table 3). These findings suggest that comorbidity
237 burden rather than late referral is a more robust predictor of death.

## 238 CKD stage and risk of progression

239 Participants in CKD stages 1 to 3 were found to be at greater risk of death before KRT than
240 progress to KRT (55.4% vs 43.5%), whereas those in stages 4 & 5 were more likely to initiate
241 KRT than die before KRT (56.5% vs 44.6%) (Table 1). Overall, mortality rates increased with
242 advancing CKD stages (Figure S1)

## 243 KFRE application and predictive accuracy

244 Among the 1,743 participants who did not fulfil the KHA eGFR criteria for referral and whose
245 UACR was available, application of the 5-year KFRE at 3% & 5% thresholds identified 708
246 (40.6%) and 509 (29.2%) as high risk, respectively. Of these, 144 (20.3%) and 126 (24.8%)
247 progressed to KRT, while 91 (12.9%) and 65 (12.8%) died without KRT (Table S6).

248 When applied to participants who met the KHA eGFR referral threshold, the KFRE at both 3%
249 and 5% thresholds, demonstrated similar predictive accuracy for KRT progression (99.6% and
250 96.6% respectively). The observed risks for KRT and death were also similar (KRT:31.0% and
251 31.9%; death:15.6% and 14.9% (Table S7).

252 These findings suggest that the eGFR threshold alone is as effective as the 5-year KFRE in
253 identifying individuals at risk of progressing to KRT as well as those who died without KRT.
254 However, the KFRE enabled identification of additional high-risk participants who would
255 otherwise be missed using the eGFR criteria alone.

256

257 **Table 1 Baseline characteristics at the time of referral and outcomes**

| **Characteristics** | Total sample | Stage 1 | Stage 2 | Stage 3A | Stage 3B | Stage 4 | Stage 5 |
|---|---|---|---|---|---|---|---|
| Participants, n (%) | 3775 | 7.9% | 11.0% | 18.6% | 31.0% | 26.2% | 5.3% |
| **Demographics** | | | | | | | |
| Age, mean | 62.5 | 48.2 | 57.6 | 62.5 | 65.3 | 65.1 | 64.3 |
| Gender, male n (%) | 2,069 (54.8) | 46.1 | 56.0 | 57.8 | 52.6 | 56.5 | 58.8 |
| Indigenous, n (%) | 327 | 32 | 49 | 52 | 86 | 89 | 19 |
| **SES Status** | | | | | | | |
| Low status n (%) | 1806 (47.8) | 48.2 | 52.2 | 49.9 | 47.4 | 45.4 | 45.7 |
| Middle status n (%) | 1006 (26.7) | 25.9 | 24.5 | 25.6 | 26.8 | 28.1 | 28.1 |
| High status n (%) | 963 (25.5) | 25.9 | 23.3 | 24.5 | 25.8 | 26.5 | 26.1 |
| BMI, n (mean) | 2500 (31.7) | 31.6 | 32.2 | 31.5 | 31.9 | 31.6 | 30.9 |
| **Primary Renal disease** | | | | | | | |
| DN, n (%) | 1,066 (28.2) | 27.6 | 30.8 | 29.9 | 26.9 | 27.8 | 28.6 |
| GN, n (%) | 473 (12.5) | 12.5 | 12.0 | 11.4 | 13.2 | 12.5 | 14.1 |
| GRD, n (%) | 183 (4.9) | 3.7 | 12.0 | 4.3 | 5.4 | 5.2 | 4.5 |
| RV, n (%) | 985 (26.1) | 23.9 | 28.4 | 28.6 | 27.0 | 23.1 | 25.6 |
| UNC, n (%) | 403 (10.7) | 10.8 | 8.4 | 9.8 | 11.4 | 12.2 | 6.5 |
| Other, n (%) | 665 (17.6) | 21.6 | 15.9 | 16.1 | 16.3 | 19.3 | 20.6 |
| **Comorbidities** | | | | | | | |
| DM, n (%) | 1,694 (44.9) | 32.0 | 42.8 | 46.0 | 47.1 | 46.3 | 44.2 |
| HTN, n (%) | 2,926 (77.5) | 77.7 | 76.7 | 74.8 | 77.4 | 80.7 | 78.9 |
| CVD, n (%) | 1,538 (40.7) | 21.2 | 32.2 | 41.1 | 43.4 | 47.4 | 37.7 |
| CAD, n (%) | 886 (23.5) | 16.8 | 19.2 | 23.3 | 25.0 | 26.1 | 23.5 |
| Obesity, n (%) | 1,366 (54.6) | 51.2 | 56.6 | 53.5 | 56.9 | 54.0 | 49.1 |
| **Comorbidity Score** | | | | | | | |
| Low comorbidity, n (%) | 1223 (32.4) | 34.0 | 33.2 | 37.1 | 29.8 | 32.0 | 32.4 |
| High comorbidity, n (%) | 2552 (67.6) | 66.0 | 66.8 | 62.9 | 70.2 | 68.0 | 67.6 |
| **Laboratory Parameters** | | | | | | | |
| eGFR, mean | 42.4 | 90 | 71.5 | 51.0 | 36.7 | 22.9 | 11.4 |
| UACR, mean | 56.1 | 44.2 | 68.5 | 48.6 | 44.5 | 66.5 | 86.8 |
| **Outcomes** | | | | | | | |
| ESKD, n (%) | 775 (20.5) | 5.7 | 11.8 | 12.4 | 16.4 | 34.4 | 54.8 |
| KRT, n (%) | 513 (13.6) | 3.7 | 8.4 | 8.8 | 10.6 | 23.4 | 34.7 |
| Total death, n (%) | 722 (19.1) | 5.7 | 10.6 | 15.1 | 18.2 | 27.1 | 36.7 |
| Death without KRT, n (%) | 598 (15.8) | 5.7 | 10.1 | 12.7 | 15.7 | 21.1 | 29.2 |

258 *SD: standard deviation; BMI: body mass index; DN: diabetic nephropathy; GN: glomerulonephritis;*
259 *GRD: genetic renal disease; RV: renovascular disease; UNC: unknown cause; DM: diabetes mellitus;*
260 *HTN: hypertension; CVD: cardiovascular disease; CAD: coronary artery disease; eGFR: estimated*
261 *glomerular filtration rate; UACR: urine albumin-to-creatinine ratio; ESKD: end-stage kidney disease;*
262 *KRT: kidney replacement therapy*

263

264 **Table 2.** Final Cox regression model

| Predictor | Hazard ratio | [95% CI] | p-value |
|---|---|---|---|
| Age at referral | 1.15 | 1.07 – 1.24 | <0.01 |
| Cardiovascular Disease | 1.9 | 1.31 – 2.75 | <0.01 |
| Late referral | 0.46 | 0.27 – 0.79 | 0.01 |

265

266 *CI: confidence interval*

267 **Table 3** Characteristics of participants who progressed to KRT

| | Total<br>N = 513 | Early Referral<br>N = 453 | Late Referral<br>N = 60 |
|---|---|---|---|
| **Parameters at time of referral** | | | |
| **Age (mean, SD)** | 56.1 ± 13.9 | 56.1 ± 13.8 | 56.2 ± 15.2 |
| **Gender (male) n (%)** | 317 (61.8) | 276 (60.9) | 41 (68.3) |
| **Indigenous, n (%)** | 76 (14.8) | 69 (15.2) | 7 (11.7) |
| **Social status** | | | |
| **Low status, n (%)** | 261 (50.9) | 229 (50.6) | 32 (53.3) |
| **Middle status, n (%)** | 107 (20.9) | 99 (21.9) | 8 (13.3) |
| **High status, n (%)** | 145 (28.3) | 125 (27.6) | 20 (33.3) |
| **BMI Category** | | | |
| **<30, n (%)** | 127 (45.2) | 105 (43.0) | 22 (59.5) |
| **≥30, n (%)** | 154 (54.8) | 139 (57.0) | 15 (40.5) |
| **Primary Renal disease** | | | |
| **DN, n (%)** | 196 (38.2) | 169 (37.3) | 27 (45) |
| **GN, n (%)** | 83 (16.2) | 71 (15.7) | 12 (20) |
| **GRD, n (%)** | 51 (9.9) | 46 (10.2) | 5 (8.3) |
| **RV, n (%)** | 90 (17.5) | 81 (17.9) | 9 (15.0) |
| **UNC, n (%)** | 24 (4.68) | 23 (5.1) | 1 (1.7) |
| **Other, n (%)** | 69 (13.5) | 63 (13.9) | 6 (10) |
| **Comorbidities** | | | |
| **DM, n (%)** | 166 (32.4) | 144 (31.8) | 22 (36.7) |
| **HTN, n (%)** | 435 (84.8) | 390 (86.1) | 45 (75) |
| **CVD, n (%)** | 278 (54.2) | 247 (54.5) | 31 (51.7) |
| **CAD, n (%)** | 151 (29.4) | 138 (30.5) | 13 (21.7) |
| **Comorbidity Score** | | | |
| **Low Comorbidity, n (%)** | 116 (22.6) | 102 (22.50) | 14 (23.3) |
| **High Comorbidity, n (%)** | 397 (77.4) | 351 (77.5) | 46 (76.7) |
| **Death after KRT, n (%)** | 124 (24.2) | 109 (24.1) | 15 (25.0) |
| **Within 12 months, n (%)** | 26 (21.0) | 23 (21.1) | 3 (20.0) |
| **≥12 months < 24 months, n (%)** | 30 (24.2) | 28 (25.7) | 2 (13.3) |
| **≥ 24 months, n (%)** | 68 (54.8) | 58 (53.2) | 10 (66.7) |
| **Laboratory Parameters** | | | |
| **eGFR (mean, SD)** | 31.0 ± 17.6 | 31.9 ± 17.6 | 24.3 ± 16.2 |
| **UACR (mean, SD)** | 102.8 ± 145.4 | 102.0 (145.7) | 109 (144.0) |
| **Risk Classification** | | | |
| **eGFR < 30, n (%)** | 297 (57.9) | 253 (55.9) | 44 (73.3) |
| **eGFR ≥ 30, n (%)** | 216 (42.1) | 200 (44.2) | 16 (26.7) |
| **UACR < 30, n (%)** | 191 (41.5) | 171 (41.9) | 20 (38.5) |
| **UACR ≥ 30, n (%)** | 269 (58.5) | 237 (58.1) | 32 (61.5) |
| **5-Year KFRE < 5, n (%)** | 73 (15.9) | 66 (16.2) | 7 (13.5) |
| **5-Year KFRE ≥ 5, n (%)** | 387 (84.1) | 342 (83.8) | 45 (86.5) |

268

269 *SD: standard deviation; BMI: body mass index; DN: diabetic nephropathy; GN: glomerulonephritis;*
270 *GRD: genetic renal disease; RV: renovascular disease; UNC: unknown cause; DM: diabetes mellitus;*
271 *HTN: hypertension; CVD: cardiovascular disease; CAD: coronary artery disease; eGFR: estimated*
272 *glomerular filtration rate; UACR: urine albumin-to-creatinine ratio; ESKD: end-stage kidney disease;*
273 *KFRE: kidney failure risk equation*

274

# Discussion

In our study, we found that participants who were in the care of nephrology clinics for more than 12 months before commencing KRT (i.e. usually considered 'timely' referral) exhibited lower survival rates than those who were referred within 12 months of KRT initiation (i.e., 'late' referral). This finding contrasts with prior studies that have reported poorer survival rates in those patients referred late using the same 12-month threshold. Previous studies have found that late referral is associated with increased mortality and poorer outcomes after starting KRT [10, 11]. The presumed benefits of early referral included better preparation for dialysis or transplantation, timely management of complications, and improved patient education. However, these studies often predate the widespread adoption of contemporary CKD management strategies [12, 24].

These results suggest that the duration of nephrology care alone may not be a sufficient explanatory factor for survival after initiation of KRT. Previous research has highlighted that even patients who have been under nephrology care for longer periods may still undergo urgent start dialysis [25-27]. Moreover, nephrology care does not always ensure optimal dialysis preparation. For example, Hamadahet al. [28] found that only 30.8% of patients under nephrology care for more than 12 months started haemodialysis with an arteriovenous fistula (AVF) . Similarly, Mendelssohnet al. [29] demonstrated that many patients who were followed by a nephrologist experienced suboptimal dialysis commencement, defined as using a temporary central dialysis catheter access for haemodialysis or peritoneal dialysis immediately after placement of a PD catheter. A follow-up study by the same group replicated the results of their study by demonstrating a 56.4% rate of suboptimal starts in early referred patients [30].

Commencing dialysis with a temporary catheter has often been cited as a key reason why patients fare poorly after starting dialysis [31]. In our analysis, we chose the 12-months cut-off

299 to define late referral to eliminate vascular access as a potential cause of poor outcomes after
300 starting dialysis, arguing that 12 months would be long enough for the nephrology clinics to
301 facilitate the creation of permanent vascular access before the start of dialysis. While it can be
302 argued that timing of referral alone (i.e., duration of pre-dialysis care) cannot be sufficient to
303 account for the superior outcomes observed in early referred patients, it is also instructive to
304 acknowledge that a longer duration of pre-dialysis care creates opportunities for an increased
305 number of visits to the nephrology clinics and allows for more time for effective treatment and
306 correction of anaemia and other complications of CKD, hence likely lowering the risk of death.
307 Moreover, frequent visits to the nephrology clinic and early exposure to multidisciplinary care
308 clinics have been demonstrated to lead to timely dialysis initiation. Early exposure allows
309 adequate and comprehensive predialysis education which in turn promotes supported modality
310 selection and timely permanent access creation [32, 33].

311 We observed a high burden of comorbidities in all participants, most of whom had an eGFR of
312 ≥30 ml/min at the time of referral. This trend was maintained in participants who progressed
313 to KRT; a higher burden of comorbidities was observed in those who were referred early
314 (commenced KRT after 12 months of referral) and in those who died after commencing KRT.
315 These results suggest that participants who had more comorbid conditions were more readily
316 referred early to nephrology practice rather than stable patients, whose main reason of referral
317 would have been uncomplicated CKD. Preexisting comorbidities have been reported to predict
318 higher mortality rates in patients starting dialysis [34]. In a prospective cohort study of patients
319 with CKD stage G5 and delayed initiation of haemodialysis, patients with a high and very high
320 Charlson Comorbidity Index (CCI) were found to have an increased risk for all-cause mortality,
321 with mortality risk increasing progressively as the CCI score increased [35]. High comorbidity
322 rate therefore appears to have been the major determinant of mortality after KRT initiation,

323 superseding the impact of late referral to nephrology services, which in our study did not predict
324 mortality.

325 Low socioeconomic status was a key characteristic observed in all stages of CKD and was also
326 a predictor of both progression to ESKD and mortality before and after initiation of KRT.
327 Studies have previously demonstrated low socioeconomic status to be a significant risk factor
328 for CKD progression and mortality, leading to higher rates of CVD and kidney failure, and
329 ultimately, increased all-cause mortality [36]. Factors that have been identified as drivers of
330 CKD progression and death in individuals from low socioeconomic background include
331 delayed diagnosis due to poor access to healthcare, unfavourable living conditions, poor
332 nutrition, and higher burden of chronic diseases [37].

333 On assessing compliance with the KHA referral criteria, we observed that 46.3% of participants
334 whose UACR was available did not fulfill either the eGFR or UACR thresholds for referral,
335 which means that they would have been either referred for reasons other than the eGFR or
336 UACR thresholds, or they may have been referred inappropriately and hence could have been
337 managed in primary care. In a similar retrospective cohort study of CKD patients over 14 years,
338 Ghimireet al. [38] observed guideline discordant rate of 59% and concluded that many of the
339 referred patients being seen by nephrologists might have had mild CKD that could have been
340 safely managed in primary care. Singhet al. [39] reported that adherence to the KDIGO
341 guidelines would result in a supply-demand mismatch and concluded that implementing the
342 guidelines may not be feasible. Kielet al. [40] came to a similar conclusion, reporting that
343 implementing KDIGO criteria would lead to more than double increase in referral rate
344 compared to actual referral. It has therefore been long argued that most current referral criteria
345 are not designed to accurately distinguish between high and low risk patients. In our study, we
346 observed that a significant proportion of participants who did not fulfill the KHA eGFR
347 threshold for referral were deemed high risk when the 5-year KFRE was applied at both the

348 3% and 5% thresholds. Additionally, when applied to participants who did not fulfill the eGFR
349 threshold for referral, the 5-year KFRE better identified participants who progressed to KRT
350 than who died.

351 The period when the participants in our study were followed up in CKD.QLD Registry in
352 relation to worldwide kidney care practice patterns is important. Substantial improvements in
353 the management of CKD in primary care settings may explain our study's differing results.
354 Enhanced education of primary care providers, improved disease definition and staging, and
355 the integration of guideline-based therapies have collectively contributed to better patient
356 outcomes. The widespread use of new pharmacological agents, particularly those with proven
357 renoprotective and cardioprotective effects, has further lessened the reliance on specialist
358 referral for optimal care.

359 These results suggest that we might be seeing the impact of improved CKD care in terms of
360 early detection and timely intervention within primary care to mitigate the risk of late referral.
361 With the advent of therapies capable of delaying the need for dialysis by decades, the necessity
362 for routine referral based solely on eGFR thresholds or arbitrary timing will need to be
363 reevaluated. Referral to nephrology may be best reserved for high-risk patients, identified
364 through validated risk prediction models like the KFRE, or those with complex needs such as
365 glomerulonephritis, vasculitis, genetic kidney diseases, or advanced CKD (stages G4 and G5)
366 requiring specialised interventions (e.g., phosphate binders, erythropoiesis-stimulating agents,
367 or preparation for KRT). Most patients referred to nephrology clinics are already receiving
368 optimised medical therapy, making the incremental benefit of specialist care less pronounced
369 in the early stages of CKD.

370 One of the key strengths of our study is that it includes important baseline characteristics of
371 participants at the time they were referred, unlike many existing studies on CKD referral
372 patterns that focus only on patient data at the start of KRT. Additionally, we were able to

373 calculate the UACR for a substantial number of participants, which allowed us to use the KFRE
374 to compare predicted outcomes with actual results. However, the retrospective nature of the
375 study meant that some clinical and laboratory data were missing from the Registry, limiting
376 the depth of our analysis. Other limitations included being unable to determine the reasons for
377 referral to nephrology clinics, making it difficult to assess whether participants who didn't meet
378 the eGFR and UACR criteria were referred appropriately. Furthermore, the Registry did not
379 record the type of vascular access used at the start of KRT, preventing us from evaluating its
380 potential effect on post-KRT mortality.

## 381 The case for a new definition of late referral: A risk-based 382 approach

383 We propose that risk stratification be incorporated into the definition of the timeliness of
384 referral of individuals with CKD from primary care to specialist nephrology services, and that
385 the definition be applicable at the point of initial nephrology consultation. This prospective
386 approach will enable timely interventions to mitigate adverse outcomes. The current
387 retrospective definition, based on variable intervals between the first nephrology visit and
388 initiation of KRT, lacks universal agreement, with timeframes ranging from 1 to 12 months.
389 This lack of a universally accepted time interval has compromised the integrity of systematic
390 reviews which have been conducted on the topic due to the heterogeneity of the time frames
391 used in the many retrospective cohort studies available in the literature. Moreover,
392 retrospective definitions offer little guidance to primary care physicians seeking optimal
393 referral timing, nor do they assist nephrologists in assessing referral appropriateness at the time
394 of the first clinic visit. Having this knowledge upfront will enable clinicians to streamline their
395 delivery of care and resources according to specific goals of care, that is, whether initiating

396 KRT preparation or focusing on slowing CKD progression and reducing cardiovascular risk
397 and death.

398 # Conclusions

399 Our analysis shows that the rate of late referral in our sample was lower than the rates that have
400 been reported in previous studies, suggesting that in the current era of enhanced CKD
401 management at the primary care level, the timing of referral to nephrology services is no longer
402 a significant determinant of post-KRT mortality. Instead, high comorbidity burden and low
403 social status seemed to be stronger predictors of mortality after KRT initiation. Other results
404 found that the accuracy of the KHA eGFR threshold of <30ml/min was comparable to the
405 KFRE 5-year risk of 3% and 5% in identifying participants who required KRT or died,
406 however, it missed a significant proportion of high-risk participants who later progressed to
407 KRT and death.

408 We conclude that the timing of referral may no longer be reliable in determining outcomes for
409 patients with CKD, given the advancements in primary care management and the availability
410 of effective renoprotective therapies and suggest that efforts be made to develop a more
411 universally accepted definition of late referral of patients with CKD from primary care to
412 specialist nephrology that incorporates risk stratification. We also encourage the empowering
413 of the primary care with targeted education programs with emphasis on guideline adherence
414 and incorporation of renoprotective agents at primary care level so that referral to secondary
415 care can be reduced.

416

417

# Author Declaration

The authors declare no competing interests.

# Author contributions

**Conceptualization**: Clyson Mutatiri, Sree Krishna Venuthurupalli, Srinivas Kondalsamy-Chennakesavan, Angela Ratsch, and Matthew McGrail.

**Methodology**: Clyson Mutatiri, Sree Krishna Venuthurupalli, Angela Ratsch Srinivas Kondalsamy-Chennakesavan, Matthew McGrail.

**Writing - original draft preparation**: Clyson Mutatiri, Matthew McGrail, Srinivas Kondalsamy-Chennakesavan, Angela Ratsch, Sree Krishna Venuthurupalli.

**Writing - review and editing**: Clyson Mutatiri, Matthew McGrail, Angela Ratsch, Srinivas Kondalsamy-Chennakesavan, Sree Krishna Venuthurupalli.

# Funding

None of the authors received any funding for their contribution to the development of this manuscript.

# Acknowledgments

We would like to thank the CKD.QLD Registry for granting us the approval of access to CKD.QLD Registry Patient Data and support for the progression of this research. We would also like to acknowledge the “in-kind” support provided by Wide Bay Hospital and Health Service to the researchers and for relevant resources including computers, telephone, and office space for the duration of this project. This study was partly supported by the Australian Government Department of Health under the Rural Health Multidisciplinary Training Programme.

# References


1. Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:3-15.doi: 10.1007/978-981-13-8871-2_1
2. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11.doi: 10.1016/j.kisu.2021.11.003
3. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473-85.doi: 10.1038/s41581-024-00820-6
4. Kushner P, Khunti K, Cebrian A, Deed G. Early identification and management of chronic kidney disease: anarrative review of the crucial role of primary care practitioners. Adv Ther. 2024;41(10):3757-70.doi: 10.1007/s12325-024-02957-z
5. Samal L, Wright A, Waikar SS, Linder JA. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis. BMC Nephrol. 2015;16(1):162.doi: 10.1186/s12882-015-0154-x
6. Wright J, Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for chronic kidney disease management in a regional Australian area of nephrologist workforce shortage. Aust J Gen Pract. 2018;47(1/2):58-62.doi: 10.3316/informit.462183610095113
7. KDIGO. Clinical practice guideline for the evaluation and management of chronic kideny disease. Kidney Disease Kid Int. 2012;3(1).doi:
8. Kidney Health Australia. Kidney Health Australia; [Available from: https://kidney.org.au/health-professionals#:~:text=We%20are%20a%20trusted%20source,waste%20product)%20in%20your%20blood.

464 9. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic
465 kidney disease: a systematic review. Am J Med. 2011;124(11):1073-80 e2.doi:
466 10.1016/j.amjmed.2011.04.026
467 10. Dhanorkar M, Prasad N, Kushwaha R, Behera M, Bhaduaria D, Yaccha M, et al.
468 Impact of early versus late referral to nephrologists on outcomes of chronic kidney
469 disease patients in northern India. Int J Nephrol. 2022;2022:4768540.doi:
470 10.1155/2022/4768540
471 11. Kim DH, Kim M, Kim H, Kim YL, Kang SW, Yang CW, et al. Early referral to a
472 nephrologist improved patient survival: prospective cohort study for end-stage renal
473 disease in Korea. PloS ONE. 2013;8(1):e55323.doi: 10.1371/journal.pone.0055323
474 12. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of
475 renal replacement therapy: a paradigm shift in the management of patients with
476 chronic renal failure. Am J Kidney Dis. 1998;31(3):398-417.doi:
477 10.1053/ajkd.1998.v31.pm9506677
478 13. Iwata Y, Okushima H, Takatsuka T, Yoshimura D, Kawamura T, Iio R, et al.
479 Duration of predialysis nephrological care and mortality after dialysis initiation. Clin
480 Exp Nephrol. 2020;24(8):705-14.doi: 10.1007/s10157-020-01889-6
481 14. Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts,.
482 Canberra: AIHW; 2024 12 Dec 2024.
483 15. Beernink JM, van Mil D, Laverman GD, Heerspink HJL, Gansevoort RT.
484 Developments in albuminuria testing: a key biomarker for detection, prognosis and
485 surveillance of kidney and cardiovascular disease-A practical update for clinicians.
486 Diabetes Obes Metab. 2025;27 Suppl 8(Suppl 8):15-33.doi: 10.1111/dom.16359
487 16. Cortinovis M, Perico N, Remuzzi G. Innovative therapeutics for renoprotection:
488 where we are. Pharmacol Rev. 2025:100060.doi: 10.1016/j.pharmr.2025.100060

489 17. Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, et al.
490 Comprehensive review of current management guidelines of chronic kidney disease.
491 Medicine (Baltimore). 2023;102(23):e33984.doi: 10.1097/MD.0000000000033984
492 18. Wehbe F, Elliott M, Levin A. Chronic kidney diseases at the crossroads: From
493 failures to future therapies. Kidney Int Rep [Internet]. 2025; Octboer 2025.doi:
494 10.1016/j.ekir.2025.09.050
495 19. Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD.QLD:
496 establishment of a chronic kidney disease [CKD] registry in Queensland, Australia.
497 BMC Nephrol. 2017;18(1):189.doi: 10.1186/s12882-017-0607-5
498 20. Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion
499 of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine
500 ratio for use in chronic kidney disease screening and prognosis: an individual
501 participant-based meta-analysis. Ann Intern Med. 2020;173(6):426-35.doi:
502 10.7326/M20-0529
503 21. Mutatiri C, Ratsch A, McGrail MR, Venuthurupalli S, Kondalsamy Chennakesavan S.
504 Referral patterns, disease progression and impact of the kidney failure risk equation
505 (KFRE) in a Queensland Chronic Kidney Disease Registry (CKD.QLD) cohort: a
506 study protocol. BMJ Open. 2022;12(2):e052790.doi: 10.1136/bmjopen-2021-052790
507 22. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational
508 assessment of accuracy of equations for predicting risk of kidney failure: a meta-
509 analysis. JAMA. 2016;315(2):164-74.doi: 10.1001/jama.2015.18202
510 23. Australian Bureau of Statistics. Socio-economic indexes for areas (SEIFA), Australia:
511 Australian Bureau of Statistics; 2021 [Available from:
512 https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-
513 indexes-areas-seifa-australia/latest-release.

514 24. Lhotta K, Zoebl M, Mayer G, Kronenberg F. Late referral defined by renal function:
515 association with morbidity and mortality. J Nephrol. 2003;16(6):855-61.doi:
516 25. Crews DC, Jaar BG, Plantinga LC, Kassem HS, Fink NE, Powe NR. Inpatient
517 hemodialysis initiation: reasons, risk factors and outcomes. Nephron Clin Pract.
518 2010;114(1):c19-28.doi: 10.1159/000245066
519 26. Marron B, Ortiz A, de Sequera P, Martin-Reyes G, de Arriba G, Lamas JM, et al.
520 Impact of end-stage renal disease care in planned dialysis start and type of renal
521 replacement therapy--a Spanish multicentre experience. Nephrol Dial Transplant.
522 2006;21 Suppl 2(suppl_2):ii51-5.doi: 10.1093/ndt/gfl191
523 27. Buck J, Baker R, Cannaby A-M, Nicholson S, Peters J, Warwick G. Why do patients
524 known to renal services still undergo urgent dialysis initiation? AJ Nephrol cross-
525 sectional survey. Nephrol Dial Transplant. 2007;22(11):3240-5.doi:
526 10.1093/ndt/gfm387
527 28. Hamadah AM, Gharaibeh K. Predialysis nephrology care and its impact on initial
528 vascular access type in hemodialysis patients in Jordan. Saudi J Kidney Dis Transpl.
529 2019;30(5):1103-10.doi: 10.4103/1319-2442.270266
530 29. Mendelssohn DC, Curtis B, Yeates K, Langlois S, MacRae JM, Semeniuk LM, et al.
531 Suboptimal initiation of dialysis with and without early referral to a nephrologist.
532 Nephrol Dial Transplant. 2011;26(9):2959-65.doi: 10.1093/ndt/gfq843
533 30. Hughes SA, Mendelssohn JG, Tobe SW, McFarlane PA, Mendelssohn DC. Factors
534 associated with suboptimal initiation of dialysis despite early nephrologist referral.
535 Nephrol Dial Transplant. 2013;28(2):392-7.doi: 10.1093/ndt/gfs431
536 31. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, et al. Delayed
537 nephrologist referral and inadequate vascular access in patients with advanced chronic

538 kidney failure. J Clin Epidemiol. 2002;55(7):711-6.doi: 10.1016/s0895-
539 4356(02)00415-8
540 32. Heaf J, Heiro M, Petersons A, Vernere B, Povlsen JV, Sørensen AB, et al. Choice of
541 dialysis modality among patients initiating dialysis: results of the Peridialysis study.
542 Clin Kidney J. 2021;14(9):2064-74.doi: 10.1093/ckj/sfaa260
543 33. Brown PA, Akbari A, Molnar AO, Taran S, Bissonnette J, Sood M, et al. Factors
544 associated with unplanned dialysis starts in patients followed by nephrologists: A
545 retropective cohort study. PloS ONE. 2015;10(6):e0130080.doi:
546 10.1371/journal.pone.0130080
547 34. Chia JMX, Goh ZS, Seow PS, Seow TY, Choo JCJ, Foo MW, et al. Psychosocial
548 factors, intentions to pursue arteriovenous sialysis access, and access outcomes: a
549 cohort study. Am J Kidney Dis. 2021;77(6):931-40.doi: 10.1053/j.ajkd.2020.09.019
550 35. Flores-Mendoza AP, Garcia-Campa M, Sanchez-Martinez C, Guerrero-Gonzalez E,
551 Rizo-Topete LM, Olivo-Gutierrez MC. Charlson comorbidity index and all-cause
552 mortality in patients with delayed hemodialysis initiation: a prospective cohort study.
553 BMC Nephrol. 2025;26(1):376.doi: 10.1186/s12882-025-04197-x
554 36. Tannor EK, Chika OU, Okpechi IG. The impact of low socioeconomic status on
555 progression of chronic kidney disease in low- and lower middle-income countries.
556 Semin Nephrol. 2022;42(5):151338.doi: 10.1016/j.semnephrol.2023.151338
557 37. Crews DC, Novick TK. Social Determinants of CKD Hotspots. Semin Nephrol.
558 2019;39(3):256-62.doi: 10.1016/j.semnephrol.2019.02.003
559 38. Ghimire A, Ye F, Hemmelgarn B, Zaidi D, Jindal KK, Tonelli MA, et al. Trends in
560 nephrology referral patterns for patients with chronic kidney disease: Retrospective
561 cohort study. PloS ONE. 2022;17(8):e0272689.doi: 10.1371/journal.pone.0272689

562 39. Singh K, Waikar SS, Samal L. Evaluating the feasibility of the KDIGO CKD referral
563 recommendations. BMC Nephrol. 2017;18(1):223.doi: 10.1186/s12882-017-0646-y
564 40. Kiel S, Weckmann G, Chenot JF, Stracke S, Spallek J, Angelow A. Referral criteria
565 for chronic kidney disease: implications for disease management and healthcare
566 expenditure-analysis of a population-based sample. BMC Nephrol.
567 2022;23(1):225.doi: 10.1186/s12882-022-02845-0

568

569

570 # Supporting information

571 **S1Table** UACR categories

572 **S2 Table** eGFR categories

573 **S3 Table** KRT by eGFR and UACR categories

574

575 **S4 Table** Log-rank test for equality of survivor functions by referral status

576 **S5 Table** Comorbidity score by KRT death and referral status

577 **S1 Fig** Distribution of death without KRT by CKD stage

578 **S6 Table** Comparison of eGFR threshold and KFRE Subgroup of participants with eGFR of
579 ≥30ml/min

580 **S7 Table** Comparison of eGFR threshold and KFRE Subgroup of participants with eGFR of
581 <30ml/min

582




# Distribution of death without KRT by CKD st




**Total number at risk**

| | | | | | |
|---|---|---|---|---|---|
| Early referral (≥12 months) | 448 | 341 | 230 | 105 | 2 |
| Late referral (<12 months) | 60 | 52 | 43 | 32 | 0 |

# Kaplan Meier survival curves after dialysis i




# Comparison of total deaths by socioeconor




Flowchart of participant selection for inclus